Keywords: Forest Labs, Daxas, Nycomed, Hyzaar, Cozaar, Teva, Merck & Co, Mylan, NuLytely
Forest Labs plunges as FDA panel gives thumbs down to Daxas; and agency clears generic Hyzaar/Cozaar for Teva and NuLytely for Mylan
Article | 08 April 2010
US drugmaker Forest Laboratories saw its share drop 8.7%, to $29.63 in late trading yesterday, after reports from Reuters and other news ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
